MXPA02004021A - A therapeutic mixture of hmg coa reductase inhibitors. - Google Patents

A therapeutic mixture of hmg coa reductase inhibitors.

Info

Publication number
MXPA02004021A
MXPA02004021A MXPA02004021A MXPA02004021A MXPA02004021A MX PA02004021 A MXPA02004021 A MX PA02004021A MX PA02004021 A MXPA02004021 A MX PA02004021A MX PA02004021 A MXPA02004021 A MX PA02004021A MX PA02004021 A MXPA02004021 A MX PA02004021A
Authority
MX
Mexico
Prior art keywords
coa reductase
reductase inhibitors
hmg coa
therapeutic mixture
therapeutic
Prior art date
Application number
MXPA02004021A
Other languages
Spanish (es)
Inventor
H Kaesemeyer Wayne
Original Assignee
Nitrosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitrosystems Inc filed Critical Nitrosystems Inc
Publication of MXPA02004021A publication Critical patent/MXPA02004021A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Therapeutic mixtures of statins alone or in combination with L arginine are described herein.
MXPA02004021A 1999-10-19 2000-10-19 A therapeutic mixture of hmg coa reductase inhibitors. MXPA02004021A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42081699A 1999-10-19 1999-10-19
PCT/US2000/041304 WO2001028499A2 (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
MXPA02004021A true MXPA02004021A (en) 2004-08-23

Family

ID=23667961

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004021A MXPA02004021A (en) 1999-10-19 2000-10-19 A therapeutic mixture of hmg coa reductase inhibitors.

Country Status (5)

Country Link
EP (1) EP1225885A4 (en)
AU (1) AU2116201A (en)
CA (1) CA2388530A1 (en)
MX (1) MXPA02004021A (en)
WO (1) WO2001028499A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
JP2002539257A (en) 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド Increased drug bioavailability in the brain
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
AU2006223212A1 (en) * 2005-03-11 2006-09-21 Hong Kong Nitric Oxide Limited Combination therapy for endothelial dysfunction, angina and diabetes
WO2014139469A1 (en) * 2013-03-15 2014-09-18 Wuhan Qr Science And Technology Development Co. Ornithine- or aspartate-containing compositions and the uses thereof
CN105246472B (en) * 2013-03-15 2018-10-12 武汉朗来科技发展有限公司 Composition containing ornithine and/or L-aminobutanedioic acid and its application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease

Also Published As

Publication number Publication date
AU2116201A (en) 2001-04-30
WO2001028499A2 (en) 2001-04-26
EP1225885A4 (en) 2004-04-21
EP1225885A2 (en) 2002-07-31
CA2388530A1 (en) 2001-04-26
WO2001028499A3 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE240334T1 (en) PYRROLOBENZODIAZEPINES
HK1200368A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor hmg coa
AP2004003189A0 (en) Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents.
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
AP2001002290A0 (en) Use of CYP2D6 inhibitors in combination therapies.
EE200100405A (en) Use of 3-hydroxy-3-methylglutaryl coenzyme as a reductase inhibitor in the preparation of a medicament for the treatment of diabetic neuropathy
MXPA05013147A (en) Solid pharmaceutical preparation.
GEP20063811B (en) Combination of Aldosterone Receptor Antagonist and HMG COA Reductase Inhibitor
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
IL163929A0 (en) Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulinsensitizer
PL374364A1 (en) Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors
AU2108601A (en) Salicylamides as serine protease inhibitors
UA66793C2 (en) Leptin as inhibitor of tumor growth
AU2003270154A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
MXPA02004021A (en) A therapeutic mixture of hmg coa reductase inhibitors.
NO996206L (en) Farnesyltransferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer
HK1043058A1 (en) Isophosphoramide mustard analogs and use thereof
BRPI0417138A (en) n-alkyl pyrroles as hmg coa reductase inhibitors
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU3512900A (en) Novel thioredoxin family active site molecules and uses therefor
AU4578197A (en) Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin
HUP0201597A2 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
SI0986387T1 (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
AU2003252358A1 (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR